
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY TEMPLATE
A. 510(k) Number:
k110738
B. Purpose for Submission:
New device
C. Measurand:
Quality control materials for multiple immunoassay analytes
D. Type of Test:
Not applicable
E. Applicant:
Microgenics Corporation
F. Proprietary and Established Names:
MAS Omni-Core
G. Regulatory Information:
Product Code Classification Regulation Section Panel
JJY Class I, reserved 862.1660 Clinical Chemistry
(75)
H. Intended Use:
1. Intended use(s):
Refer to indications for use below
2. Indication(s) for use:
Thermo Scientific MAS Omni-Core is intended for use an assayed control for
monitoring assay conditions in many clinical laboratory determinations. Include
1

[Table 1 on page 1]
	Product Code			Classification			Regulation Section			Panel	
JJY			Class I, reserved			862.1660			Clinical Chemistry
(75)		

--- Page 2 ---
Omni-Core with patient serum specimens when assaying for any of the listed
constituents. Assay values are provided for the specific systems listed. The user
can compare observations with their expected ranges as a means of assuring
consistent performance of reagent and instrument.
3. Special conditions for use statement(s):
For in vitro diagnostic use
For prescription use
4. Special instrument requirements:
For use with the specific systems listed in the package insert
I. Device Description:
The Omni-Core controls are liquid stable control material prepared from human serum.
Analyte levels are adjusted with various animal extracts and non-protein materials
including drugs, drug metabolites, and purified chemicals. Amylase, alanine
aminotransferase, creatine kinase and lipase are obtained from porcine tissue; alkaline
phosphatase and gamma glutamyl transferase are from bovine tissue; lactate
dehydrogenase is from avian tissue. Preservatives and stabilizers are added to maintain
product integrity. Controls are provided in frozen liquid form
Omni-CORE is prepared from components which are derived from human source
material have been tested and found non-reactive for Hepatitis B Surface Antigen
(HBsAg), Hepatitis C (HCV), HIV-1 and HIV-2.
The control is offered in three levels (1, 2, or 3) or in combination.
J. Substantial Equivalence Information:
1. Predicate device name(s):
MAS®Chem-TRAK H
2. Predicate 510(k) number(s):
k092051
3. Comparison with predicate
2

--- Page 3 ---
Candidate Device Predicate
k110738 Mas Chem TRAK H
k092051
Indications for Intended for monitoring Same
Use assay conditions in
many clinical
laboratory
determinations.
Analyte Multiple analytes Same
Matrix Human serum Same
Format Frozen Liquid Frozen liquid
Number of levels 3 Same
Shelf life 3 years -20 degrees C 2.5 years at -20
degrees C
Assigned Acetaminophen Acetaminophen
analytes:
Albumin Albumin
ALK Phos. (Alkaline Alkaline Phosphatase,
Phosphatase)
alpha-1-Acid
Glycoprotein
Alpha-1-Antitrypsin
Alpha-2-Macroglobulin
Alanine Alanine
Aminotransferase Aminotransferase
Amikacin Amikacin
Amylase Amylase –
Antistreptolysin 0
(ASO) -
Apolipoprotein A1 Apolipoprotein A
(APO A)
Apolipoprotein B Apolipoprotein B
(APO B)
Aspartate Aspartate
Aminotransferase Aminotransferase,
Beta 2 Microglobulin
Bile Acids
Direct Bilirubin, Direct Bilirubin,
Total Bilirubin Total Bilirubin
Blood Urea Nitrogen, Blood Urea Nitrogen
C3 Complement C3 Complement
C4 Complement C4 Complement
3

[Table 1 on page 3]
	Candidate Device
k110738	Predicate
Mas Chem TRAK H
k092051
Indications for
Use	Intended for monitoring
assay conditions in
many clinical
laboratory
determinations.	Same
Analyte	Multiple analytes	Same
Matrix	Human serum	Same
Format	Frozen Liquid	Frozen liquid
Number of levels	3	Same
Shelf life	3 years -20 degrees C	2.5 years at -20
degrees C

[Table 2 on page 3]
Assigned
analytes:	Acetaminophen	Acetaminophen
	Albumin	Albumin
	ALK Phos. (Alkaline
Phosphatase)	Alkaline Phosphatase,
	alpha-1-Acid
Glycoprotein	
	Alpha-1-Antitrypsin	
	Alpha-2-Macroglobulin	
	Alanine
Aminotransferase	Alanine
Aminotransferase
	Amikacin	Amikacin
	Amylase	Amylase –
	Antistreptolysin 0
(ASO) -	
	Apolipoprotein A1	Apolipoprotein A
(APO A)
	Apolipoprotein B	Apolipoprotein B
(APO B)
	Aspartate
Aminotransferase	Aspartate
Aminotransferase,
	Beta 2 Microglobulin	
	Bile Acids	
	Direct Bilirubin,	Direct Bilirubin,
	Total Bilirubin	Total Bilirubin
	Blood Urea Nitrogen,	Blood Urea Nitrogen
	C3 Complement	C3 Complement
	C4 Complement	C4 Complement

--- Page 4 ---
Caffeine Caffeine
Calcium Calcium
Carbamazepine Carbamazepine –
Ceruloplasmin
Chloride Chloride
Cholesterol Cholesterol
Creatine Kinase Creatine Kinase
CO2 CO2
Copper
Cortisol
C-Reactive Protein C-Reactive Protein,
(CRP) CRP
Creatinine Creatinine
Digoxin Digoxin
Disopyramide Disopyramide
Ethanol Ethanol
Ethosuximide Ethosuximide
Ferritin Ferritin
Gentamicin Gentamicin
Gamma Gamma
Glutamyltransferase Glutamyltransferase
Glucose Glucose
Haptoglobin Haptoglobin
HDL Cholesterol HDL Cholesterol
- Human Chorionic
Gonadotrophin
IgA IgA
IgE -
IgG IgG
IgM IgM
-
-
Iron Iron
Lactic Acid Lactic Acid
LDH LDH
LDL-Cholesterol LDL-Cholesterol
Lidocaine Lidocaine
Lipase Lipase
Lipoprotein (a) Lipoprotein (LpA)
Lithium Lithium
Magnesium Magnesium
Methotrexate Methotrexate
N-Acetylprocainamide, N-Acetylprocainamide
Osmolality Osmolality
4

[Table 1 on page 4]
	Caffeine	Caffeine
	Calcium	Calcium
	Carbamazepine	Carbamazepine –
	Ceruloplasmin	
	Chloride	Chloride
	Cholesterol	Cholesterol
	Creatine Kinase	Creatine Kinase
	CO2	CO2
	Copper	
	Cortisol	
	C-Reactive Protein
(CRP)	C-Reactive Protein,
CRP
	Creatinine	Creatinine
	Digoxin	Digoxin
	Disopyramide	Disopyramide
	Ethanol	Ethanol
	Ethosuximide	Ethosuximide
	Ferritin	Ferritin
	Gentamicin	Gentamicin
	Gamma
Glutamyltransferase	Gamma
Glutamyltransferase
	Glucose	Glucose
	Haptoglobin	Haptoglobin
	HDL Cholesterol	HDL Cholesterol
	-	Human Chorionic
Gonadotrophin
	IgA	IgA
	IgE	-
	IgG	IgG
	IgM	IgM
	-	
	-	
	Iron	Iron
	Lactic Acid	Lactic Acid
	LDH	LDH
	LDL-Cholesterol	LDL-Cholesterol
	Lidocaine	Lidocaine
	Lipase	Lipase
	Lipoprotein (a)	Lipoprotein (LpA)
	Lithium	Lithium
	Magnesium	Magnesium
	Methotrexate	Methotrexate
	N-Acetylprocainamide,	N-Acetylprocainamide
	Osmolality	Osmolality

--- Page 5 ---
Phenobarbital Phenobarbital
Phenytoin Phenytoin
Phosphorus Phosphorus
Potassium Potassium
Prealbumin
Primidone
Procainamide
Pseudocholinesterase Pseudocholinesterase
Quinidine Quinidine
RF
Salicylate Salicylate
Sodium Sodium
T3 uptake T3 uptake
Thyroxine Total T4 Thyroxine Total T4
Theophylline Theophylline
Thyroid Stimulating Thyroid Stimulating
Hormone, TSH Hormone, TSH
Tobramycin Tobramycin
Total Iron Binding Total Iron Binding
Capacity Capacity
Total Protein Total Protein
Transferrin Transferrin
Triglycerides Triglycerides
Tricyclic Tricyclic
Antidepressants Antidepressants
Uric Acid Uric Acid
Valproic Acid Valproic Acid
Vancomycin Vancomycin
Zinc
K. Standard/Guidance Document Referenced (if applicable):
None were referenced
L. Test Principle:
Not applicable
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
5

[Table 1 on page 5]
	Phenobarbital	Phenobarbital
	Phenytoin	Phenytoin
	Phosphorus	Phosphorus
	Potassium	Potassium
	Prealbumin	
	Primidone	
	Procainamide	
	Pseudocholinesterase	Pseudocholinesterase
	Quinidine	Quinidine
		
	RF	
	Salicylate	Salicylate
	Sodium	Sodium
	T3 uptake	T3 uptake
	Thyroxine Total T4	Thyroxine Total T4
	Theophylline	Theophylline
	Thyroid Stimulating
Hormone, TSH	Thyroid Stimulating
Hormone, TSH
	Tobramycin	Tobramycin
	Total Iron Binding
Capacity	Total Iron Binding
Capacity
	Total Protein	Total Protein
	Transferrin	Transferrin
	Triglycerides	Triglycerides
	Tricyclic
Antidepressants	Tricyclic
Antidepressants
	Uric Acid	Uric Acid
	Valproic Acid	Valproic Acid
	Vancomycin	Vancomycin
	Zinc	

--- Page 6 ---
a. Precision/Reproducibility:
Not applicable
b. Linearity/assay reportable range:
Not applicable
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Analyte components:
Target values: Level 1 Level 2 Level 3 units
Acetaminophen 25 82.5 140 ug/mL
Albumin 2.5 5 7.5 g/dL
Alkaline Phosphatase 45 197.5 350 U/L
alpha-1-Acid 43 85 127 mg/dL
Glycoprotein
alpha-1-Antitrypsin 77 153.5 230 mg/dL
alpha-2- 90 178 280 mg/dL
Macroglobulin
ALT 40 120 200 U/L
Amikacin 5 17.5 30 ug/mL
Amylase 90 320 550 U/L
Antistreptolysin O 89 194.5 300 IU/mL
Apolipoprotein A1 90 160 230 mg/dL
Apolipoprotein B 46 103 160 mg/dL
AST 40 155 270 U/L
Beta 2 Microglobulin 1.5 6.5 10 mg/L
Bile Acids 4.5 8 10 umol/L
Direct (DBIL) 0.6 2.38 3.75 mg/dL
Bilirubin,
Total (BILT) 1 4.1 7.2 mg/dL
BUN 15 40 65 mg/dL
C3 Complement 79 170.5 262 mg/dL
C4 Complement 20 35 50 mg/dL
Caffeine 5 12 20 ug/mL
Calcium 6.5 9.25 12 mg/dL
Carbamazepine 4 9 14 ug/mL
Ceruloplasmin 17 38.5 60 mg/dL
Chloride 85 95 105 mMol/L
Cholesterol 115 167.5 220 mg/dL
CK 90 345 600 U/L
CO2 16 24 32 mMol/L
Cortisol 4 19.5 35 ug/dL
6

[Table 1 on page 6]
Acetaminophen	25	82.5	140	ug/mL
Albumin	2.5	5	7.5	g/dL
Alkaline Phosphatase	45	197.5	350	U/L
alpha-1-Acid
Glycoprotein	43	85	127	mg/dL
alpha-1-Antitrypsin	77	153.5	230	mg/dL
alpha-2-
Macroglobulin	90	178	280	mg/dL
ALT	40	120	200	U/L
Amikacin	5	17.5	30	ug/mL
Amylase	90	320	550	U/L
Antistreptolysin O	89	194.5	300	IU/mL
Apolipoprotein A1	90	160	230	mg/dL
Apolipoprotein B	46	103	160	mg/dL
AST	40	155	270	U/L
Beta 2 Microglobulin	1.5	6.5	10	mg/L
Bile Acids	4.5	8	10	umol/L
Direct (DBIL)
Bilirubin,	0.6	2.38	3.75	mg/dL
Total (BILT)	1	4.1	7.2	mg/dL
BUN	15	40	65	mg/dL
C3 Complement	79	170.5	262	mg/dL
C4 Complement	20	35	50	mg/dL
Caffeine	5	12	20	ug/mL
Calcium	6.5	9.25	12	mg/dL
Carbamazepine	4	9	14	ug/mL
Ceruloplasmin	17	38.5	60	mg/dL
Chloride	85	95	105	mMol/L
Cholesterol	115	167.5	220	mg/dL
CK	90	345	600	U/L
CO2	16	24	32	mMol/L
Cortisol	4	19.5	35	ug/dL

--- Page 7 ---
C-Reactive Protein 0.8 3.9 7 mg/dL
Creatinine 1 4 7 mg/dL
Digoxin 1 1.85 2.7 ng/mL
Disopyramide 1.5 3 5 ug/mL
Ethanol 20 100 180 mg/dL
Ethosuximide 35 100 150 ug/mL
Ferritin 25 195 370 ng/mL
Gentamicin 1.7 4.35 7 ug/mL
GGT 40 95 150 mg/dL
Glucose 65 207.5 350 mg/dL
Haptoglobin 64 139 214 mg/dL
HDL Cholesterol 30 50 70 mg/dL
IgA 134 268 402 mg/dL
IgE 152 286 420 IU/mL
IgG 541 1270 2000 mg/dL
IgM 58 109.5 161 mg/dL
Iron 75 152.5 240 ug/dL
Lactic Acid 1.25 3.875 6.5 mMol/L
LDH 100 225 350 U/L
LDL-Cholesterol 45 72.5 100 mg/dL
Lidocaine 1.5 4.75 8 ug/mL
Lipase 225 312.5 400 U/L
Lipoprotein (a) 4 9.5 15 mg/dL
Lithium 0.8 1.5 2.2 mEq/dL
Magnesium 1 2.75 4.5 mg/dL
Methotrexate 0.35 2.5 2.8 uMol/L
NAPA 3 8 13 ug/mL
Phenobarbital 10 30 50 ug/mL
Phenytoin 5 13.5 22 ug/mL
Phosphorus 2.2 4.85 7.5 mg/dL
Potassium 2.5 4.25 6 mEq/L
Prealbumin 12 28.5 45 mg/dL
Primidone 4 11 18 ug/mL
Procainamide 3 7.5 12 ug/mL
Pseudocholinesterase 2.5 6.5 10.5 U/mL
Quinidine 1.5 3.75 6 ug/mL
RF 45 72.5 100 IU/mL
Salicylate 7 11 15 mg/dL
Sodium 115 130 145 mEq/dL
Thyroxine, Total T4 7 12 17 ug/dL
Theophylline 5 15 25 ug/mL
Tobramycin 1.5 4.5 7.5 ug/mL
Total Protein 4.5 8.25 12 g/dL
Transferrin 150 285 420 mg/dL
Triglycerides 90 155 220 mg/dL
7

[Table 1 on page 7]
C-Reactive Protein	0.8	3.9	7	mg/dL
Creatinine	1	4	7	mg/dL
Digoxin	1	1.85	2.7	ng/mL
Disopyramide	1.5	3	5	ug/mL
Ethanol	20	100	180	mg/dL
Ethosuximide	35	100	150	ug/mL
Ferritin	25	195	370	ng/mL
Gentamicin	1.7	4.35	7	ug/mL
GGT	40	95	150	mg/dL
Glucose	65	207.5	350	mg/dL
Haptoglobin	64	139	214	mg/dL
HDL Cholesterol	30	50	70	mg/dL
IgA	134	268	402	mg/dL
IgE	152	286	420	IU/mL
IgG	541	1270	2000	mg/dL
IgM	58	109.5	161	mg/dL
Iron	75	152.5	240	ug/dL
Lactic Acid	1.25	3.875	6.5	mMol/L
LDH	100	225	350	U/L
LDL-Cholesterol	45	72.5	100	mg/dL
Lidocaine	1.5	4.75	8	ug/mL
Lipase	225	312.5	400	U/L
Lipoprotein (a)	4	9.5	15	mg/dL
Lithium	0.8	1.5	2.2	mEq/dL
Magnesium	1	2.75	4.5	mg/dL
Methotrexate	0.35	2.5	2.8	uMol/L
NAPA	3	8	13	ug/mL
Phenobarbital	10	30	50	ug/mL
Phenytoin	5	13.5	22	ug/mL
Phosphorus	2.2	4.85	7.5	mg/dL
Potassium	2.5	4.25	6	mEq/L
Prealbumin	12	28.5	45	mg/dL
Primidone	4	11	18	ug/mL
Procainamide	3	7.5	12	ug/mL
Pseudocholinesterase	2.5	6.5	10.5	U/mL
Quinidine	1.5	3.75	6	ug/mL
RF	45	72.5	100	IU/mL
Salicylate	7	11	15	mg/dL
Sodium	115	130	145	mEq/dL
Thyroxine, Total T4	7	12	17	ug/dL
Theophylline	5	15	25	ug/mL
Tobramycin	1.5	4.5	7.5	ug/mL
Total Protein	4.5	8.25	12	g/dL
Transferrin	150	285	420	mg/dL
Triglycerides	90	155	220	mg/dL

--- Page 8 ---
Thyroid Stimulating 2.5 9 14 uIU/mL
Hormone, TSH
Tricyclic 40 100 180 ng/mL
Antidepressants
(TCA)
Uric Acid 3.3 7.15 11 mg/dL
Valproic Acid 25 72.5 120 ug/mL
Vancomycin 7.5 21.25 35 ug/mL
In addition, the following analytes are not set to a specific range, but are assigned as
found in human serum. These include: copper, total iron binding capacity, osmolality,
T3-uptake, and zinc.
Value Assignment:
Value assignment ranges for controls are established at ±20% or ±3SDs around the mean,
whichever is broader. Narrower ranges (such as ±2SDs or ±15%) may be used as long as
the min and max values in the data set are within the established ranges. Data are
collected from two or three different laboratories over two or three separate days.
Stability:
Stability under the following conditions are evaluated.
Stability condition Stability evaluated by: Stability claim:
Open Vial Stability Recovery difference fresh 14 days for bilirubin
between 2-8°C vs. 30 day open vial. (30 days for all other analytes)
Closed Vial
Stability Recovery difference fresh
between 2-8°C vs. 30 day closed vial. 30 days
Closed vial stability Recovery at zero time versus
at–20°C recovery at test date. Currently labeled for 3 years.
The package insert states that laboratories should establish internal mean and range
criteria based upon local test system evaluation and tolerance limits.
d. Detection limit:
Not applicable
e. Analytical specificity:
8

[Table 1 on page 8]
Thyroid Stimulating
Hormone, TSH	2.5	9	14	uIU/mL
Tricyclic
Antidepressants
(TCA)	40	100	180	ng/mL
Uric Acid	3.3	7.15	11	mg/dL
Valproic Acid	25	72.5	120	ug/mL
Vancomycin	7.5	21.25	35	ug/mL

--- Page 9 ---
Not applicable
f. Assay cut-off:
Not applicable
2. Comparison studies:
a. Method comparison with predicate device:
Not applicable
b. Matrix comparison:
Not applicable
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable
b. Clinical specificity:
Not applicable
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable
4. Clinical cut-off:
Not applicable
5. Expected values/Reference range:
The expected values are provided in the labeling for each specific lot.
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports
substantial equivalence decision.
9